IO-TKI Treatment Regimens in the Treatment of mRCC

Panelists discuss how immunotherapy–tyrosine kinase inhibitor (IO-TKI) combination regimens have revolutionized the treatment landscape for metastatic renal cell carcinoma (mRCC) by offering improved response rates, survival outcomes, and quality of life compared with traditional monotherapies.

EP: 1.KEYNOTE-564: Updates in RCC Treatment and Diagnostic Imaging Pearls

EP: 2.Localized Renal Cell Carcinoma: Current Treatment Considerations

Now Viewing

EP: 3.IO-TKI Treatment Regimens in the Treatment of mRCC

EP: 4.Recent Trials Guiding mRCC Treatment

EP: 5.Sequencing Therapies for Patients With Renal Cell Carcinoma

EP: 6.Final Insights in Care for Patients With Renal Cell Carcinoma

Recent Videos